Abstract P142: Erythropoietin Administered after Resuscitation from Cardiac Arrest Improves Myocardial Function in a Rat Model of CPR
Introduction: Erythropoietin (EPO) administered prior to or following either myocardial or cerebral infarction minimizes the severity of ischemic injury. We hypothesized that when EPO is administered after resuscitation from cardiac arrest, post resuscitation myocardial function and survival would improve.
Methods: In an established model of cardiac arrest, ventricular fibrillation (VF) was electrically induced in 32 male SD rats weighing 520±20 g and left untreated for 8 minutes, followed by 6 minutes of pre-cordial compressions and attempted defibrillation. Resuscitated animals were randomized to receive either EPO 5000 units/kg, which was injected into the right atrium, or saline as a control. The primary investigator was blinded to the randomization. Dp/dt40 and −dp/dt were calculated based on continuously measured left ventricular pressure. Ejection fraction (EF) measured echocardiographically and blood gases were both measured hourly for four hours. Survival was observed at 72 hours.
Results: Twenty animals were successfully resuscitated and randomized. EPO significantly improved both EF and contractility as measured by dp/dt40. It also reduced the severity of post resuscitation hypo-perfusion based on arterial blood lactate measurements (Figure⇓). However, no statistically significant differences in survival were observed. Figure⇓. Box plot of dp/dt40, EF and arterial lactic acid.
Conclusion: EPO improved myocardial function and minimized the severity of post-resuscitation perfusion failure. However, no persuasive survival benefit was demonstrated.